

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

Atty. Docket No.  
99,424-T1

Serial No.  
Not Assigned

Applicant:

Jeff Zablocki et al.

Filing Date:  
Concurrently  
Herewith

Group:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclas s	Filing Date if Appropriate
PL	5,189,027	2/23/93	Miyashita et al.			
	5,593,975	1/14/97	Cristalli			
	4,956,345	9/11/90	Miyasaka et al.			
	5,270,304	12/14/93	Kogi et al.			
	5,459,254	10/17/95	Yamaguchi et al.			
	5,705,491	1/6/98	Yamada			
	5,770,716	6/23/98	Khan et al.			
	5,939,543	8/17/99	Morozumi et al.			
↓	6,214,807	4/10/01	Zablocki et al.			
PL	6,026,317	2/15/00	Verani			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
PL	965,411	4/1/75	Canada				
PL	Hei 5[1993]-9197	1/19/93	Japan				
PL	0 354 638	2/14/90	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PL		Marumoto, et al., "Synthesis and Coronary Vadodilating Activity of 2-Substituted Adenosines", <i>Chem. Pharm. Bull.</i> 23(4): 759-774 (1975).
----	--	--

EXAMINER	DATE CONSIDERED
	11-22-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

Serial No.

99,424-T11

Not Assigned

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use several sheets if necessary)

**Applicant:**

Jeff Zablocki et al.

**Filing Date:**

Concurrently  
Herewith

**Group:**

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclas s	Filing Date if Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

PL		Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3'5'-Cyclic Phosphate Analogs", Chem. Pharm. Bull. 27(4) 990-1003 (1979).
1		Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", Bioorganic & Medicinal Chemistry, 3:1377-1382 (1995).
		Mager, et al., "Molecular simulation applied to 2-(N'alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A <sub>2</sub> Agnonists", Eur J. Med. Chem, 30:15-25 (1995).
✓		Cristalli et al., "2-Alkynl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A <sub>2</sub> Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", J. Med. Chem, 37:1720-1726 (1994).
PL		Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenoines: A Novel Class of Selective Adenosine A <sub>2</sub> Receptor Agonists with Potent Antihypertensive Effects", J. Med. Chem. 35:241-252 (1992).

EXAMINER

DATE CONSIDERED

11-22-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.